Antonella Ravaggi

List of Publications by Year
in descending order

121 papers	4,556 citations	76326 40 h-index	123424 61 g-index
122 all docs	122 docs citations	122 times ranked	6037 citing authors

#	Article	IF	Citations
1	Landscape of somatic single-nucleotide and copy-number mutations in uterine serous carcinoma. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 2916-2921.	7.1	275
2	Mutational landscape of uterine and ovarian carcinosarcomas implicates histone genes in epithelialâ€"mesenchymal transition. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 12238-12243.	7.1	181
3	Induction of Human Papillomavirus-Specific CD4+ and CD8+ Lymphocytes by E7-Pulsed Autologous Dendritic Cells in Patients with Human Papillomavirus Type 16- and 18-Positive Cervical Cancer. Journal of Virology, 1999, 73, 5402-5410.	3.4	142
4	Interleukin-10 Increases Th1 Cytokine Production and Cytotoxic Potential in Human Papillomavirus-Specific CD8+ Cytotoxic T Lymphocytes. Journal of Virology, 2000, 74, 4729-4737.	3.4	137
5	Diagnostic and prognostic impact of serum HE4 detection in endometrial carcinoma patients. British Journal of Cancer, 2011, 104, 1418-1425.	6.4	134
6	Human Papillomavirus Type 16 and 18 E7-Pulsed Dendritic Cell Vaccination of Stage IB or IIA Cervical Cancer Patients: a Phase I Escalating-Dose Trial. Journal of Virology, 2008, 82, 1968-1979.	3.4	124
7	Serum Human Epididymis Protein 4 and Risk for Ovarian Malignancy Algorithm as New Diagnostic and Prognostic Tools for Epithelial Ovarian Cancer Management. Cancer Epidemiology Biomarkers and Prevention, 2011, 20, 2496-2506.	2.5	112
8	Hepatitis C virus RNA and antibody response in the clinical course of acute hepatitis C virus infection. Hepatology, 1992, 16, 877-881.	7.3	105
9	Differential gene expression profiles between tumor biopsies and short-term primary cultures of ovarian serous carcinomas: Identification of novel molecular biomarkers for early diagnosis and therapy. Gynecologic Oncology, 2006, 103, 405-416.	1.4	104
10	HE4 and epithelial ovarian cancer: Comparison and clinical evaluation of two immunoassays and a combination algorithm. Clinica Chimica Acta, 2011, 412, 1447-1453.	1.1	104
11	Trop-2 overexpression as an independent marker for poor overall survival in ovarian carcinoma patients. European Journal of Cancer, 2010, 46, 944-953.	2.8	94
12	HPV16/18 E7-pulsed dendritic cell vaccination in cervical cancer patients with recurrent disease refractory to standard treatment modalities. Gynecologic Oncology, 2006, 100, 469-478.	1.4	90
13	HE4, CA125 and risk of ovarian malignancy algorithm (ROMA) as diagnostic tools for ovarian cancer in patients with a pelvic mass: An Italian multicenter study. Gynecologic Oncology, 2016, 141, 303-311.	1.4	87
14	Effects of concurrent cisplatinum administration during radiotherapy vs. radiotherapy alone on the immune function of patients with cancer of the uterine cervix. International Journal of Radiation Oncology Biology Physics, 2000, 48, 997-1006.	0.8	84
15	Gene expression profile of ovarian serous papillary carcinomas: identification of metastasis-associated genes. American Journal of Obstetrics and Gynecology, 2007, 196, 245.e1-245.e11.	1.3	82
16	Circulating miRNA landscape identifies miR-1246 as promising diagnostic biomarker in high-grade serous ovarian carcinoma: A validation across two independent cohorts. Cancer Letters, 2017, 388, 320-327.	7.2	73
17	Phenotypic and Functional Analysis of Tumor-Infiltrating Lymphocytes Compared with Tumor-Associated Lymphocytes from Ascitic Fluid and Peripheral Blood Lymphocytes in Patients with Advanced Ovarian Cancer. Gynecologic and Obstetric Investigation, 2001, 51, 254-261.	1.6	72
18	Human epididymis protein 4 as a serum marker for diagnosis of endometrial carcinoma and prediction of clinical outcome. Clinical Chemistry and Laboratory Medicine, 2012, 50, 2189-2198.	2.3	72

#	Article	IF	Citations
19	A KRAS variant is a biomarker of poor outcome, platinum chemotherapy resistance and a potential target for therapy in ovarian cancer. Oncogene, 2012, 31, 4559-4566.	5.9	71
20	Effects of interferon treatment on the antiviral T-cell response in hepatitis C virus genotype 1b- and genotype 2c-infected patients. Hepatology, 1997, 26, 792-797.	7.3	61
21	Intracellular localization of full-length and truncated hepatitis C virus core protein expressed in mammalian cells. Journal of Hepatology, 1994, 20, 833-836.	3.7	58
22	Transduction and Utility of the Granulocyte-Macrophage Colony-Stimulating Factor Gene into Monocytes and Dendritic Cells by Adeno-Associated Virus. Journal of Interferon and Cytokine Research, 2000, 20, 21-30.	1.2	57
23	lncRNAs as Novel Indicators of Patients' Prognosis in Stage I Epithelial Ovarian Cancer: A Retrospective and Multicentric Study. Clinical Cancer Research, 2017, 23, 2356-2366.	7.0	57
24	Radiation-enhanced expression of E6/E7 transforming oncogenes of human papillomavirus-16 in human cervical carcinoma. Cancer, 1998, 83, 2346-2352.	4.1	55
25	Polymerase Îµ (POLE) ultra-mutation in uterine tumors correlates with T lymphocyte infiltration and increased resistance to platinum-based chemotherapy in vitro. Gynecologic Oncology, 2017, 144, 146-152.	1.4	55
26	Induction of ovarian tumor-specific CD8+ cytotoxic T lymphocytes by acid-eluted peptide-pulsed autologous dendritic cells. Obstetrics and Gynecology, 2000, 96, 422-430.	2.4	54
27	miRNA Landscape in Stage I Epithelial Ovarian Cancer Defines the Histotype Specificities. Clinical Cancer Research, 2013, 19, 4114-4123.	7.0	53
28	FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients. Journal of Experimental and Clinical Cancer Research, 2017, 36, 63.	8.6	53
29	Whole-exome sequencing of cervical carcinomas identifies activating ERBB2 and PIK3CA mutations as targets for combination therapy. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 22730-22736.	7.1	52
30	Investigation of the Ovarian and Prostate Cancer Peptidome for Candidate Early Detection Markers Using a Novel Nanoparticle Biomarker Capture Technology. AAPS Journal, 2010, 12, 504-518.	4.4	51
31	Identification of stably expressed reference small nonâ€coding <scp>RNA</scp>s for micro<scp>RNA</scp> quantification in highâ€grade serous ovarian carcinoma tissues. Journal of Cellular and Molecular Medicine, 2016, 20, 2341-2348.	3.6	50
32	Mutational landscape of primary, metastatic, and recurrent ovarian cancer reveals c-MYC gains as potential target for BET inhibitors. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 619-624.	7.1	49
33	Integrated mutational landscape analysis of uterine leiomyosarcomas. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	48
34	Expression of Surface Antigens During the Differentiation of Human Dendritic Cells vs Macrophages from Blood Monocytes in vitro. Immunobiology, 1999, 200, 187-204.	1.9	47
35	Claudin-7 expression in human epithelial ovarian cancer. International Journal of Gynecological Cancer, 2008, 18, 1262-1271.	2.5	45
36	Trop-2 protein overexpression is an independent marker for predicting disease recurrence in endometrioid endometrial carcinoma. BMC Clinical Pathology, 2012, 12, 22.	1.8	45

#	ARTICLE	IF	CITATIONS
37	Virological response to interferon treatment in hepatitis C virus carriers with normal aminotransferase levels and chronic hepatitis. Hepatology, 1997, 26, 1012-1017.	7.3	44
38	In vitro induction of tumor-specific human lymphocyte antigen class Iâ€"restricted CD8+ cytotoxic T lymphocytes by ovarian tumor antigenâ€"pulsed autologous dendritic cells from patients with advanced ovarian cancer. American Journal of Obstetrics and Gynecology, 2000, 183, 601-609.	1.3	44
39	Outbreak of Hepatitis C Virus Infection in Patients With Hematologic Disorders Treated With Intravenous Immunoglobulins: Different Prognosis According to the Immune Status. Blood, 1997, 90, 1309-1314.	1.4	43
40	Direct PCR amplification of HCV RNA from human serum.. Genome Research, 1992, 1, 291-292.	5.5	42
41	Increased levels of interleukin-10 and transforming growth factor-beta in the plasma and ascitic fluid of patients with advanced ovarian cancer. BJOG: an International Journal of Obstetrics and Gynaecology, 2001, 108, 804-808.	2.3	41
42	Trefoil factor 3: a novel serum marker identified by gene expression profiling in high-grade endometrial carcinomas. British Journal of Cancer, 2008, 99, 768-773.	6.4	40
43	Serum S100A6 Concentration Predicts Peritoneal Tumor Burden in Mice with Epithelial Ovarian Cancer and Is Associated with Advanced Stage in Patients. PLoS ONE, 2009, 4, e7670.	2.5	38
44	Emergence of hepatitis B virus S gene mutant in a liver transplant recipient. Journal of Medical Virology, 1995, 47, 410-415.	5.0	37
45	Profiling cancer gene mutations in longitudinal epithelial ovarian cancer biopsies by targeted next-generation sequencing: a retrospective study. Annals of Oncology, 2015, 26, 1363-1371.	1.2	37
46	Genome-wide study of salivary miRNAs identifies miR-423-5p as promising diagnostic and prognostic biomarker in oral squamous cell carcinoma. Theranostics, 2021, 11, 2987-2999.	10.0	37
47	Cancer antigen 125, human epididymis 4, kallikrein 6, osteopontin and soluble mesothelin-related peptide immunocomplexed with immunoglobulin M in epithelial ovarian cancer diagnosis. Clinical Chemistry and Laboratory Medicine, 2013, 51, 1815-24.	2.3	32
48	Induction of tumour-specific CD8+ cytotoxic T lymphocytes by tumour lysate-pulsed autologous dendritic cells in patients with uterine serous papillary cancer. British Journal of Cancer, 2002, 86, 151-157.	6.4	31
49	Prognostic Significance of Vascular Endothelial Growth Factor Serum Determination in Women with Ovarian Cancer. ISRN Obstetrics & Gynecology, 2012, 2012, 1-11.	1.2	31
50	Quantification of hepatitis C virus RNA by competitive amplification of RNA from denatured serum and hybridization on microtiter plates. Journal of Clinical Microbiology, 1995, 33, 265-269.	3.9	31
51	Increased levels of interleukin-10 and transforming growth factor-Î² in the plasma and ascitic fluid of patients with advanced ovarian cancer. British Journal of Obstetrics and Gynaecology, 2001, 108, 804-808.	0.9	30
52	Tumor-Infiltrating Lymphocytes Contain Higher Numbers of Type 1 Cytokine Expressors and DR+ T Cells Compared with Lymphocytes from Tumor Draining Lymph Nodes and Peripheral Blood in Patients with Cancer of the Uterine Cervix. Gynecologic Oncology, 2001, 81, 424-432.	1.4	30
53	Trop-2 Overexpression in Poorly Differentiated Endometrial Endometrioid Carcinoma: Implications for Immunotherapy With hRS7, a Humanized Antiâ€"Trop-2 Monoclonal Antibody. International Journal of Gynecological Cancer, 2011, 21, 1613-1621.	2.5	30
54	FXYD5 (Dysadherin) upregulation predicts shorter survival and reveals platinum resistance in high-grade serous ovarian cancer patients. British Journal of Cancer, 2019, 121, 584-592.	6.4	30

#	Article	IF	Citations
55	Identification of Optimal Reference Genes for Gene Expression Normalization in a Wide Cohort of Endometrioid Endometrial Carcinoma Tissues. PLoS ONE, 2014, 9, e113781.	2.5	29
56	Epidermal growth factor receptor detection in serum and saliva as a diagnostic and prognostic tool in oral cancer. Laryngoscope, 2017, 127, E408-E414.	2.0	29
57	Distribution of viral genotypes in Italy determined by hepatitis C virus typing by DNA immunoassay. Journal of Clinical Microbiology, 1994, 32, 2280-2284.	3.9	29
58	Evaluation of hepatitis delta virus RNA levels during interferon therapy by analysis of polymerase chain reaction products with a nonradioisotopic hybridization assay. Hepatology, 1992, 15, 685-689.	7.3	28
59	Overexpression of mammaglobin B in epithelial ovarian carcinomas. Gynecologic Oncology, 2007, 105, 578-585.	1.4	28
60	Infiltration by CXCL10 Secreting Macrophages Is Associated With Antitumor Immunity and Response to Therapy in Ovarian Cancer Subtypes. Frontiers in Immunology, 2021, 12, 690201.	4.8	28
61	Development and Therapeutic Effect of Adoptively Transferred T Cells Primed by Tumor Lysate-Pulsed Autologous Dendritic Cells in a Patient with Metastatic Endometrial Cancer. Gynecologic and Obstetric Investigation, 2000, 49, 194-203.	1.6	27
62	Mammaglobin B expression in human endometrial cancer. International Journal of Gynecological Cancer, 2008, 18, 1090-1096.	2.5	27
63	Class III Î²-tubulin overexpression in ovarian clear cell and serous carcinoma as a maker for poor overall survival after platinum/taxane chemotherapy and sensitivity to patupilone. American Journal of Obstetrics and Gynecology, 2013, 209, 62.e1-62.e9.	1.3	26
64	The effects of irradiation on the expression of a tumour rejection antigen (heat shock protein gp96) in human cervical cancer. International Journal of Radiation Biology, 1998, 73, 699-704.	1.8	25
65	Development and characterization of a human single-chain antibody fragment against claudin-3: a novel therapeutic target in ovarian and uterine carcinomas. American Journal of Obstetrics and Gynecology, 2009, 201, 70.e1-70.e9.	1.3	24
66	Mammaglobin B (SCGB2A1) is a novel tumour antigen highly differentially expressed in all major histological types of ovarian cancer: implications for ovarian cancer immunotherapy. British Journal of Cancer, 2013, 109, 462-471.	6.4	24
67	Clinical significance of serum hepatitis C virus (HCV) RNA as marker of HCV infection. Journal of Clinical Microbiology, 1994, 32, 3008-3012.	3.9	24
68	Virological characterization and liver histology in HCV positive subjects with normal and elevated ALT levels. Liver, 1997, 17, 133-138.	0.1	23
69	Identical TP53 mutations in pelvic carcinosarcomas and associated serous tubal intraepithelial carcinomas provide evidence of their clonal relationship. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2016, 469, 61-69.	2.8	23
70	Functional characterization of epithelial ovarian cancer histotypes by drug target based protein signaling activation mapping: Implications for personalized cancer therapy. Proteomics, 2015, 15, 365-373.	2.2	22
71	Expression of CD56 by human papillomavirus E7-specific CD8+ cytotoxic T lymphocytes correlates with increased intracellular perforin expression and enhanced cytotoxicity against HLA-A2-matched cervical tumor cells. Clinical Cancer Research, 2001, 7, 804s-810s.	7.0	22
72	A prognostic regulatory pathway in stage I epithelial ovarian cancer: new hints for the poor prognosis assessment. Annals of Oncology, 2016, 27, 1511-1519.	1.2	20

#	Article	IF	Citations
73	Hepatitis C virus genotypes in northern Italy: clinical and virological features. Journal of Clinical Microbiology, 1996, 34, 2822-2825.	3.9	20
74	Mammaglobin B is an independent prognostic marker in epithelial ovarian cancer and its expression is associated with reduced risk of disease recurrence. BMC Cancer, 2009, 9, 253.	2.6	19
75	Human Kallikrein 5: An Interesting Novel Biomarker in Ovarian Cancer Patients That Elicits Humoral Response. International Journal of Gynecological Cancer, 2009, 19, 1015-1021.	2.5	19
76	RERT: A Novel Regression Tree Approach to Predict Extrauterine Disease in Endometrial Carcinoma Patients. Scientific Reports, 2017, 7, 10528.	3.3	19
77	Secretion of vascular endothelial growth factor in adenocarcinoma and squamous cell carcinoma of the uterine cervix. Obstetrics and Gynecology, 1999, 94, 78-82.	2.4	18
78	Long-term follow-up of and infectivity in blood donors with hepatitis C antibodies and persistently normal alanine aminotransferase levels. Transfusion, 1995, 35, 108-111.	1.6	17
79	Effects of Retinoic Acid Combined with Irradiation on the Expression of Major Histocompatibility Complex Molecules and Adhesion/Costimulation Molecules ICAM-1 in Human Cervical Cancer. Gynecologic Oncology, 1998, 70, 195-201.	1.4	17
80	Correlation between serological immune response analyzed by a new ELISA for HPV-16/18 E7 oncoprotein and clinical characteristics of cervical cancer patients. Archives of Virology, 2006, 151, 1899-1916.	2.1	17
81	Gene Expression Profiling of Olfactory Neuroblastoma Helps Identify Prognostic Pathways and Define Potentially Therapeutic Targets. Cancers, 2021, 13, 2527.	3.7	17
82	MAL gene overexpression as a marker of high-grade serous ovarian carcinoma stem-like cells that predicts chemoresistance and poor prognosis. BMC Cancer, 2017, 17, 366.	2.6	16
83	Expression profiles of PRKG1, SDF2L1 and PPP1R12A are predictive and prognostic factors for therapy response and survival in high–grade serous ovarian cancer. International Journal of Cancer, 2020, 147, 565-574.	5.1	15
84	Claudin3 is localized outside the tight junctions in human carcinomas. Oncotarget, 2018, 9, 18446-18453.	1.8	15
85	Evaluation of a novel human IgG1 anti-claudin3 antibody that specifically recognizes its aberrantly localized antigen in ovarian cancer cells and that is suitable for selective drug delivery. Oncotarget, 2015, 6, 34617-34628.	1.8	15
86	The HIV-protease inhibitor saquinavir reduces proliferation, invasion and clonogenicity in cervical cancer cell lines. Oncology Letters, 2016, 12, 2493-2500.	1.8	14
87	Development, characterization and distribution of adoptively transferred peripheral blood lymphocytes primed by human papillomavirus 18 E7--pulsed autologous dendritic cells in a patient with metastatic adenocarcinoma of the uterine cervix. European Journal of Gynaecological Oncology (discontinued), 2000, 21, 17-23.	0.2	13
88	Effects of retinoic acid combined with interferon-gamma on the expression of major-histocompatibility-complex molecules and intercellular adhesion molecule-1 in human cervical cancer. , 1998, 75, 254-258.		10
89	Kinase-driven metabolic signalling as a predictor of response to carboplatin–paclitaxel adjuvant treatment in advanced ovarian cancers. British Journal of Cancer, 2017, 117, 494-502.	6.4	10
90	Utility Serum Marker HE4 for the Differential Diagnosis Between Endometriosis and Adnexal Malignancy. International Journal of Gynecological Cancer, 2016, 26, 52-55.	2.5	9

#	Article	IF	Citations
91	Transcriptional Characterization of Stage I Epithelial Ovarian Cancer: A Multicentric Study. Cells, 2019, 8, 1554.	4.1	9
92	Low Expression of Claudin-7 as Potential Predictor of Distant Metastases in High-Grade Serous Ovarian Carcinoma Patients. Frontiers in Oncology, 2020, 10, 1287.	2.8	9
93	Comprehensive Profiling of Hypoxia-Related miRNAs Identifies miR-23a-3p Overexpression as a Marker of Platinum Resistance and Poor Prognosis in High-Grade Serous Ovarian Cancer. Cancers, 2021, 13, 3358.	3.7	9
94	Differential pattern of sequence heterogeneity in the hepatitis C virus E1 and E2/NS1 proteins. Journal of Hepatology, 1994, 21, 858-865.	3.7	8
95	Retinoic acid up-regulates the expression of major histocompatibility complex molecules and adhesion/costimulation molecules (specifically, intercellular adhesion molecule ICAM-1) in human cervical cancer. American Journal of Obstetrics and Gynecology, 1998, 179, 1020-1025.	1.3	8
96	Secretion of Vascular Endothelial Growth Factor in Adenocarcinoma and Squamous Cell Carcinoma of the Uterine Cervix. Obstetrics and Gynecology, 1999, 94, 78-82.	2.4	8
97	Outbreak of Hepatitis C Virus Infection in Patients With Hematologic Disorders Treated With Intravenous Immunoglobulins: Different Prognosis According to the Immune Status. Blood, 1997, 90, 1309-1314.	1.4	8
98	Comparison of competitive and non-competitive reverse transcription-polymerase chain reaction (RT-PCR) for the quantification of hepatitis C virus (HCV) RNA. Journal of Virological Methods, 1997, 65, 123-129.	2.1	7
99	Utility of human epididymis protein 4 serum marker for the detection of adnexal malignancy: a multicentric prospective study. European Journal of Cancer Prevention, 2017, 26, 346-350.	1.3	7
100	Novel immunotherapeutic strategies in gynecologic oncology. Dendritic cell-based immunotherapy for ovarian cancer. Minerva Ginecologica, 2002, 54, 133-44.	0.8	7
101	<scp>L1CAM</scp> expression as a predictor of platinum response in high‐risk endometrial carcinoma. International Journal of Cancer, 2022, 151, 637-648.	5.1	7
102	Molecular analysis of mixed infection with hepatitis C virus and human immunodeficiency virus in a patient infected simultaneously. Journal of Medical Virology, 1996, 50, 276-282.	5.0	6
103	Secretoglobin expression in ovarian carcinoma: lipophilin B gene upregulation as an independent marker of better prognosis. Journal of Translational Medicine, 2013, 11, 162.	4.4	6
104	Pre-treatment Serum HE4 Level as a Novel Independent Prognostic Biomarker for Uterine Cervical Carcinoma Patients. Frontiers in Oncology, 2020, 10, 584022.	2.8	6
105	The Claudin-Low Subtype of High-Grade Serous Ovarian Carcinoma Exhibits Stem Cell Features. Cancers, 2021, 13, 906.	3.7	6
106	PD-L1 quantification across tumor types using the reverse phase protein microarray: implications for precision medicine. , 2021, 9, e002179.		6
107	Immunotherapy for the prevention of high-risk oral disorders malignant transformation: the IMPEDE trial. BMC Cancer, 2021, 21, 561.	2.6	5
108	Influence of maternal CD4 levels on the predictive value of virus load over mother-to-child transmission of human immunodeficiency virus type 1 (HIV-1). , 1999, 58, 59-62.		4

#	Article	IF	Citations
109	Heterogeneity of the Hepatitis C Virus Genome. Journal of Infectious Diseases, 1991, 163, 1383-1384.	4.0	3
110	Effects of retinoic acid combined with interferon-gamma on the expression of a tumor rejection antigen (heat shock protein gp96) in human cervical cancer. International Journal of Gynecological Cancer, 1998, 8, 158-163.	2.5	2
111	Induction of Ovarian Tumor-Specific CD8+ Cytotoxic T Lymphocytes by Acid-Eluted Peptide-Pulsed Autologous Dendritic Cells. Obstetrics and Gynecology, 2000, 96, 422-430.	2.4	2
112	Diagnosis of viral hepatitis with a nonisotopic hybridization assay. Nuclear Medicine and Biology, 1994, 21, 441-447.	0.6	1
113	Expression and cytokine mediated modulation of adhesion/costimulation molecules ICAM-1(CD54) and LFA-3(CD58) in human ovarian cancer. International Journal of Gynecological Cancer, 1997, 7, 273-278.	2.5	1
114	Prospective study of mother‐to‐infant transmission of hepatitis C virus (HCV) infection. Journal of Medical Virology, 1998, 54, 12-19.	5.0	1
115	VEGF-D Serum Level as a Potential Predictor of Lymph Node Metastasis and Prognosis in Vulvar Squamous Cell Carcinoma Patients. Frontiers in Oncology, 2022, 12, 818613.	2.8	1
116	Genetic evolution of the hypervariable region 1 in hepatitis C virus carriers with normal aminotransferase activities. Research in Virology, 1998, 149, 439-444.	0.7	0
117	964P Gene expression profiling to improve prognostic characterization of olfactory neuroblastoma and to define new targetable pathways. Annals of Oncology, 2020, 31, S680.	1.2	0
118	Abstract 4584: Verification of ovarian cancer biomarker candidates by nanoparticle-capture MRM. , 2010, , .		0
119	Abstract B18: miRNA landscape analysis of stage I EOC, identifies miR-199a-5p associated to poor prognosis in grade 3 subgroup. , 2013, , .		0
120	Protein network mapping of glucose metabolism in ovarian cancer.. Journal of Clinical Oncology, 2014, 32, 5550-5550.	1.6	0
121	Rapid screening of recombinant plasmids with a non-radioisotopic hybridization assay. BioTechniques, 1992, 13, 506-8.	1.8	0